This study used ultra-sensitive blood-based immunoassays on Quanterix Single Molecule Array platforms to quantify serum big tau, brain-derived tau (BD-tau), and neurofilament light chain (NfL). Big tau and BD-tau were measured on an HD-X analyser, while NfL in neuropathy patients was measured on an SR-X analyser. The assays enabled detection of low picogram-per-milliliter concentrations of each analyte in serum.
Participants included patients with peripheral neuropathies and central nervous system (CNS) diseases plus healthy controls (HC). Group sizes were: Guillain-Barré syndrome (GBS, n=81), Miller Fisher syndrome (MFS, n=20), Charcot-Marie-Tooth disease (CMT, n=102), chronic inflammatory demyelinating polyneuropathy (CIDP, n=43), multiple sclerosis (MS, n=159), Alzheimer disease (AD, n=20), and healthy controls (HC, n=41).
Serum big tau concentrations were highest in GBS compared with CNS disease groups reported: GBS showed higher big tau than AD (11.4 vs 2.4 pg/mL, p<0.0001) and higher than MS (11.4 vs 9.0 pg/mL, p=0.01). Big tau levels in GBS were similar to those in CIDP and CMT, consistent with enrichment of this isoform in PNS disorders.
Serum BD-tau showed a different pattern: BD-tau in GBS was higher than in CIDP (3.0 vs 2.3 pg/mL, p=0.006) and higher than in MS (3.0 vs 1.7 pg/mL, p<0.0001). BD-tau in GBS was similar to CMT, but substantially lower than in AD (3.0 vs 9.8 pg/mL, p<0.0001), aligning BD-tau with CNS-derived pathology in AD.
Serum NfL levels were elevated in GBS relative to CIDP (32.5 vs 13.0 pg/mL, p=0.0002), CMT (32.5 vs 12.3 pg/mL, p<0.0001), and HC (32.5 vs 7.6 pg/mL, p<0.0001), indicating prominent axonal injury in GBS compared with these groups.
Compared with GBS, patients with Miller Fisher syndrome (MFS) displayed a distinct profile: markedly higher serum BD-tau (12.7 vs 3.0 pg/mL, p=0.003), lower big tau (5.4 vs 11.4 pg/mL, p=0.002), and an increased NfL/big tau ratio. NfL concentrations were higher in MFS than in GBS (118.3 vs 32.5 pg/mL), but this difference did not reach statistical significance in this sample (p=0.16). The elevated BD-tau together with reduced big tau and higher NfL/big tau ratio in MFS is interpreted by the authors as suggestive of CNS involvement alongside relative preservation of the PNS.
In the GBS cohort, higher serum BD-tau correlated with measures of early clinical severity: Medical Research Council (MRC) score at 1 week, I-RODS at 4 weeks, maximum Guillain-Barré syndrome disability score (GBS-DS), and GBS-DS at 4 weeks. Tau biomarkers did not show correlations with long-term clinical outcomes in this report.
Both higher BD-tau and higher big tau were associated with respiratory failure requiring mechanical ventilation (BD-tau: 8.6 vs 2.9 pg/mL, p=0.019; big tau: 19.7 vs 10.7 pg/mL, p=0.007). Additionally, higher BD-tau was associated with mortality (10.9 vs 2.9 pg/mL, p=0.003).
The differing distributions of the analytes support a compartmental interpretation: elevated big tau in peripheral neuropathies relative to CNS diseases supports its role as a PNS-specific biomarker. Elevated BD-tau and very high NfL/big tau ratios in MFS point toward CNS involvement in that syndrome, whereas GBS shows a biomarker profile more consistent with PNS-predominant pathology but with BD-tau increases that relate to early clinical severity and poor short-term outcomes.
The authors conclude that measurement of big tau, BD-tau, and NfL in serum can help differentiate peripheral from central nervous system involvement in neuropathic disorders. Big tau appears informative as a PNS-enriched blood biomarker; BD-tau tracks CNS-derived tau and relates to early severity and adverse outcomes in GBS. The distinct biomarker constellation in MFS suggests CNS pathology with relative PNS preservation.
Ethical approvals for the study are reported, funding sources and competing interests are disclosed, and the authors state that anonymized data not published in the article are available upon reasonable request. The article does not report long-term biomarker correlations beyond the early timepoints indicated, and no additional mechanistic or interventional data are provided in the source.